Danish cancer specialist Genmab’s (OMX: GEN) stock took a hit after US healthcare giant Johnson & Johnson (NYSE: JNJ) opted not to license its HexaBody-CD38 (GEN301), despite its promising trial results.
Genmab’s shares closed down 8.3% at 1,522 kroner following the announcement on Monday, and fell a further 6% to 1,429.50 kroner this morning.
While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab’s rigorous portfolio prioritization, Genmab said it will not pursue further clinical development of HexaBody-CD38
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze